stockrow
Saturday 7 November 2026
Export VOR’s income statement to Excel — free account
Vor Biopharma Inc.
19.84
1.18
+6.32%
Follow VOR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 26 | 26 | 26 | 0.0% | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | (4) | (11) | (43) | (69) | (92) | — | — | — | (116) | +117.0% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (4) | (11) | 0 | 0 | 0 | (118) | (117) | (696) | 628 | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (0.11) | (0.34) | (4,611.40) | (42.00) | (46.60) | (35.00) | (34.00) | (70.50) | (379.10) | +151.8% | ||||||
| Cash flow | — | — | (0.07) | (0.27) | (3,860.85) | (42.15) | (43.08) | 0.00 | 0.00 | 0.00 | (27.99) | n/m | ||||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | (0.07) | (0.27) | (3,860.85) | (42.15) | (43.08) | 0.00 | 0.00 | 0.00 | (27.99) | n/m | ||||||
| Book value | — | — | (0.18) | 0.21 | 5,135.21 | 131.83 | 126.81 | 0.00 | 0.00 | 0.00 | 51.70 | n/m | ||||||
| Shares, m | — | — | 37 | 37 | 0 | 2 | 2 | 3 | 3 | 2 | 30 | (35.9%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (3) | (10) | (36) | (69) | (85) | — | — | — | (95) | +137.8% | |||||
| Capex | — | — | — | (1) | (4) | (4) | (8) | — | — | — | — | +124.5% | ||||||
| Free cash flow | — | — | (3) | (10) | (36) | (69) | (85) | — | — | — | (95) | +137.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | (7) | 5 | 39 | 204 | 224 | — | — | — | 149 | n/m | |||||
| Net debt | — | — | 4 | (6) | (30) | (189) | (191) | — | — | — | (124) | n/m | ||||||
| Shareholders’ equity | — | — | (7) | 8 | 48 | 216 | 251 | — | — | — | 175 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (824.63) | (232.84) | (882.09) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +824.6 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| ROE | — | — | 34.32 | 104.24 | 113.31 | (87.66) | (39.45) | 0.00 | 0.00 | 0.00 | (69.27) | (34.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Vor Biopharma Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DRTS Alpha Tau Medical Ltd. | $1.2B | — (loss-making) | — | — | n/m | −30.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MNKD MannKind Corporation | $1.2B | — (loss-making) | — (loss-making) | +24.04% (above 0%: growing) | n/m | −267.69% (below 0%: shrinking) | 0.00% | (2.14%) | Compare |
| AVLN Avalyn Pharma Inc. | $1.2B | — (loss-making) | — | — | n/m | — | — | 0.00% | Compare |
| INBX Inhibrx Biosciences, Inc. | $1.2B | — (loss-making) | — (loss-making) | +992.44% (above 0%: growing) | n/m | +0.12% (above 0%: growing) | 100.00% | 0.00% | Compare |
| VOR Vor Biopharma Inc. | $1.2B | — (loss-making) | — | — | n/m | −47.59% (below 0%: shrinking) | 0.00% | — | |
| RAPP Rapport Therapeutics, Inc. | $1.1B | — (loss-making) | — | — | n/m | −64.75% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| SGP SpyGlass Pharma, Inc. | $1.1B | — (loss-making) | — | — | n/m | −100.49% (below 0%: shrinking) | — | 0.00% | Compare |
| VSTM Verastem, Inc. | $1.1B | — (loss-making) | — (loss-making) | +113.59% (above 0%: growing) | n/m | +24.50% (above 0%: growing) | 0.00% | (313.28%) | Compare |
| SPTX Seaport Therapeutics, Inc | $1.1B | — (loss-making) | — | — | n/m | −43.81% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $1.2B | — | — | +113.59% | — | −43.81% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 27 April 2026
Ownership
Directors and executive officers, together
less than 1%
RA Capital Management, L.P.
19.99%
TCG Crossover
10.47%
Remegen Co., Ltd.
9.99%
ForGrowth III PA B.V.
9.99%
Venrock Healthcare Capital Partners III, L.P.
9.89%
Verve Capital Limited
9.18%
Reprogrammed Interchange LLC
6.36%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement